-
“IDENTIFICATION AND CLASSIFICATION OF EXCLUSIVE PROTEINS FROM HER-2 POSITIVE BREAST CANCER SENSITIVE TO TREATMENT WITH TRASTUZUMAB”
Vol 1, 2020 -131584 -
PROTEOMIC ANALYSIS OF HER-2 POSITIVE BREAST CANCER RESISTANT TO TRASTUZUMAB TREATMENT
Vol 1, 2020 -131582 -
Inhibition of the Histone Deacetylase activity impacts on Glioblastoma secretoma and disrupts the molecular signature of the Tumor Extracellular Matrix
Vol 1, 2020 -131355
Publications in other proceedings
-
XVIII SO 2024
INVESTIGATING THE ROLE OF β1 INTEGRIN IN HER-2 POSITIVE BREAST CANCER
-
FRONTIERS 2024
Proteomic characterization following compressive sciatic nerve injury in mice treated with inosine
-
XVI SO 2022
THE MOLECULAR SIGNATURE OF EXOSOME-RELATED PROTEINS IS DISRUPTED BY HISTONE DEACETYLASE ACTIVITY INHIBITION IN THE GLIOBLASTOMA SECRETOME: IN SILICO AND IN VIVO CHARACTERIZATIO
-
XVI SO 2022
INCREASED MIGRATORY CAPACITY OF HER2+ BREAST CANCER TUMOR CELLS AFTER TREATMENT WITH TRASTUZUMAB
-
XVI SO 2022
EXPRESSION EVALUATION OF HER-2 AND β1 INTEGRIN IN HER-2+ BREAST CANCER CELLS LINES AFTER TREATMENT WITH TRASTUZUMAB
Streamline your Scholarly Event
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
